What Does Ongoing Monitoring for Tysabri-Associated PML Look Like?

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Science to Occupational and Patient Risk Awareness

If you or a loved one is on Tysabri, you may wonder what ongoing monitoring for progressive multifocal leukoencephalopathy (PML) actually involves. Decades of pharmacovigilance have established that regular MRI scans and neurological assessments are central to detecting early signs of PML. This page explains the standard monitoring schedule, key risk indicators, and what patients should discuss with their healthcare team.

Understanding Tysabri and Its Link to Progressive Multifocal Leukoencephalopathy

Tysabri (natalizumab) is a monoclonal antibody used to treat multiple sclerosis and Crohn's disease. Its prescribing information carries a boxed warning stating that Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV) that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML typically only occurs in patients who are immunocompromised, and the warning emphasizes that healthcare professionals should monitor patients for any new sign or symptom suggestive of PML and withhold Tysabri immediately at the first such indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three specific risk factors for developing PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered in the context of expected benefit when initiating and continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the PML risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Clinical trial data documented PML in three patients who received Tysabri. Two cases occurred among 1869 multiple sclerosis patients treated for a median of 120 weeks; these patients had also received interferon beta-1a (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The third case occurred after eight doses in one of 1043 Crohn's disease patients evaluated for PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The clinical presentation of PML can include progressive neurological deficits such as weakness, gait disturbance, cognitive impairment, and visual changes. The FDA Adverse Event Reporting System (FAERS) data for Tysabri show that among the most frequently reported adverse events are fatigue, multiple sclerosis relapse, headache, gait disturbance, fall, memory impairment, asthenia, malaise, balance disorder, hypoesthesia, muscular weakness, cognitive disorder, and mobility decreased (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports are not specific to PML, they reflect the types of neurological symptoms that may overlap with early PML signs.

Mechanism of PML Development and Risk Factors

The mechanistic pathway linking Tysabri to PML involves its pharmacological action. Tysabri is an alpha-4 integrin antagonist that inhibits the migration of lymphocytes into the central nervous system. This immunosuppressive effect can impair immune surveillance against JCV, allowing the virus to reactivate and cause lytic infection of oligodendrocytes, leading to demyelination and the characteristic brain lesions of PML. The risk is highest in patients with anti-JCV antibodies, indicating prior exposure to the virus, and increases with longer treatment duration and prior immunosuppressant use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Regarding the adequacy of warnings, the boxed warning on the Tysabri label explicitly states the increased risk of PML, identifies the three known risk factors, and instructs healthcare professionals to monitor patients and withhold dosing at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The label also notes that PML usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The restricted distribution program is designed to ensure that patients and prescribers are informed of these risks. However, for patients who develop PML despite these warnings, questions may arise about whether the warnings were adequately communicated or whether the risk-benefit assessment was properly conducted in their individual case.

Legal Considerations for North Carolina Patients

For affected patients in North Carolina, attorney-related considerations include the need to establish a clear timeline between Tysabri exposure and the onset of PML symptoms. The boxed warning indicates that PML can occur after varying durations of therapy, with risk increasing beyond two years of treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). In clinical trials, PML was observed after a median of 120 weeks in multiple sclerosis patients and after eight doses in a Crohn's disease patient (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Medical records documenting the start date of Tysabri therapy, any prior immunosuppressant use, anti-JCV antibody status, and the date of first PML symptoms are critical for evaluating the temporal relationship. Additionally, documentation of whether the patient was monitored according to the TOUCH program requirements and whether any neurological symptoms were promptly evaluated can be relevant. Patients who develop PML may face severe disability or death, and legal action may seek compensation for medical expenses, lost income, and pain and suffering. An attorney experienced in pharmaceutical injury cases can help assess whether the manufacturer provided adequate warnings and whether the prescribing physician followed appropriate monitoring protocols. The evidence from the FDA label and FAERS data provides a foundation for understanding the known risks and the clinical context of PML associated with Tysabri.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Frequently Asked Questions

What is Tysabri and how is it linked to PML?

Tysabri (natalizumab) is a monoclonal antibody used to treat multiple sclerosis and Crohn's disease. It carries a boxed warning for increased risk of progressive multifocal leukoencephalopathy (PML), a rare brain infection caused by the JC virus that often leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the risk factors for developing PML while on Tysabri?

Three specific risk factors have been identified: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What legal options do North Carolina patients have if they develop PML from Tysabri?

Patients may seek compensation for medical expenses, lost income, and pain and suffering. An attorney can help assess whether the manufacturer provided adequate warnings and whether the prescribing physician followed monitoring protocols. Key evidence includes medical records documenting Tysabri exposure, PML diagnosis, and adherence to the TOUCH program.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.